Vital Therapies reported $10.4M in Current Liabilities for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Biomarin Pharmaceutical BMRN:US $ 464.73M 25.69M
Dynavax Technologies DVAX:US $ 345.2M 121M
Enanta Pharmaceuticals ENTA:US $ 23.04M 7.7M
Epizyme EPZM:US $ 34.95M 4.01M
Insmed INSM:US $ 113.82M 11.43M
Intercept Pharmaceuticals ICPT:US $ 151.43M 0.39M
Mirati Therapeutics MRTX:US $ 119.15M 4.42M
Omeros OMER:US $ 38.5M 3.44M
Orasure Technologies OSUR:US $ 65.49M 9.9M
Quidel QDEL:US $ 900M 407.34M
Regulus Therapeutics RGLS:US $ 5.83M 1.13M
Revance Therapeutics RVNC:US $ 77.23M 6.16M
Ultragenyx Pharmaceutical RARE:US $ 220.64M 53.4M
United Therapeutics UTHR:US $ 331.5M 38.9M
Vital Therapies VTL:US $ 10.4M 1.06M
Xoma XOMA:US $ 8.42M 534K